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http://dx.doi.org/10.1016/j.gmbhs.2Abstract Colorectal cancer (CRC) is one of themost commonmalignancies and the thirdmajor
cause of cancer-related deaths in Taiwan. In 2011, more than 13,000 new cases of CRC were
diagnosed and more than 4921 Taiwanese died from CRC. Standards of rectal cancer diagnosis
and treatment have changed considerably during the past decade. Although surgery is still
considered the cornerstone of rectal cancer treatment, high rates of local recurrence and unsat-
isfactory survival rates (40e55% at 5 years) have remained significant problems, even in patients
subjected to curative resection. Preoperative chemoradiotherapy (CRT) is currently considered
the standard treatment for locally advanced rectal cancer, and oncological outcomes using this
approach are encouraging, with rates of local and distant recurrence at the five-year mark being
6e9% and 33e36%, respectively. The peculiar aspects of this approach are related to clinical
over-staging, whichmay result in unnecessary neoadjuvant treatment in almost 18e20% of cases
as proven in a trial conducted in Germany. This article focuses on the results of studies assessing
the predictors of responses for locally advanced rectal cancer patients following CRT. The ability
to predict response to preoperative CRT can prevent unnecessary treatment and protect poorly
responding patients from the side effects of neoadjuvant treatment.
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Predictors for rectal cancer following CCRT 19Introduction
have been correlated with high recurrence rates. Further-Colorectal cancer (CRC) is one of the most common types of
cancer in Asian countries, and its incidence and mortality
have significantly increased in the past several decades.1,2
In addition to being one of the most common malignancies
in Taiwan, CRC is also the third major cause of cancer-
related deaths in Taiwan. In 2011, more than 13,000 new
cases of CRC were diagnosed and more than 4921 Taiwa-
nese died from CRC.3
Standards for the diagnosis and treatment of rectal cancer
have changed considerably during the past decade. Although
surgery remains the cornerstone of rectal cancer treatment,
high rates of local recurrence and unsatisfactory survival rates
(40e55% at 5 years) continue to pose significant problems,
even in patients subjected to curative resection.4 Recent
prospective randomized studies with large sample sizes and
long-term follow-up have demonstrated that multimodal
treatment strategies [such as neoadjuvant radiotherapy and
chemoradiotherapy (CRT)] are superior to surgery alone or
surgery with postoperative CRT in terms of local control,
feasibility, and toxicity.5,6 Preoperative CRT for locally
advanced rectal cancer (LARC) provides several potential ad-
vantages, including reduction in radiation-induced toxicity,
decrease in tumor volume, introduction of downstaging, in-
crease in the possibility of R0 resection, enhanced probability
of anal sphincter preservation by shrinking large distal tumors,
reduction in local recurrence, and increase in survival rates.7,8
Preoperative CRT is currently considered the standard treat-
ment for LARC. The oncological outcomes using this approach
areencouraging,with ratesof local anddistant recurrenceat5
years being 6e9% and 33e36%, respectively.6,9,10 However,
only a subgroup of patients treated with preoperative CRT
respond to treatment.6,11 The other subgroup consists of
nonresponders who do not benefit from the therapy and who
may be treated using alternative means. The peculiar aspects
of this approach are related to clinical over-staging, which
may result in unnecessary neoadjuvant treatment in almost
18e20% of cases, as proven in a trial in Germany.6 Currently,
patient selection for preoperative neoadjuvant therapy de-
pendsmainly onclinical parameters, including the stageof the
disease. However, most of these parameters do not have a
predictive impact on therapy response. Thus, the implication
of potential factors predicting histopathological response to
treatment is a major issue.
This article reviews updated information regarding the
prognostic and molecular aspects of LARC patients who
have received preoperative CRT, and evaluates the signifi-
cance of such aspects in neoadjuvant therapy and their
impact on therapeutic strategies.Conventional predictive factor in LARC with
preoperative CRT
Carcinoembryonic antigen
Given its reliability and cost-effectiveness, serum carci-
noembryonic antigen (s-CEA) is currently themostwidely used
tumor marker, especially in CRC.12 Most s-CEA studies in CRC
patientshave focusedontheprognosticeffect ofpreoperatives-CEA concentration, and elevated preoperative s-CEA levels
more, postoperative s-CEA monitoring has been valuable for
the early detection of recurrence after curative surgery and
the assessment of responses to chemotherapy in patientswith
metastatic CRC.13 Increased preoperative and early post-
operative s-CEA concentrations after curative resection are
associated with more frequent systemic failure and poorer
survival rates in rectal cancer patients.13 In general, elevated
CEA levels measured during treatment indicate disease pro-
gression, but with some exceptions. An increase in CEA alone
should not be considered as evidence of disease progression,
especially immediately after chemotherapy is recommended,
because chemotherapy may transiently elevate CEA levels.14
Several studies have investigated the utility of pre- and
post-CRT s-CEA concentrations as predictors of response to
preoperative CRT.15,16 In 2011, Kim et al17 evaluated 333
rectal cancer patients who received preoperative CRT fol-
lowed by surgery, and assessed the clinical significance of a
reduction in s-CEA concentration ratio prior to and after
preoperative CRT. They demonstrated that the reduction
ratio of pre- to post-CRT s-CEA concentrations may be an
independent prognostic factor for disease-free survival
following preoperative CRT and surgery in rectal cancer
patients with initial s-CEA > 6 mg/L.17 In LARC, CEA levels
are of potential clinical value as a predictor of response to
preoperative CRT and as an independent prognostic factor
after preoperative CRT and curative surgery.Molecular (biological) markers
Several molecular markers have been proposed for
measuring the radio- and chemo-sensitivity of rectal cancer.
We categorized the surrogate biomarkers into six subgroups.
(1) Resistant to chemoradiotherapy: CD133 and cyclo-
oxygenase-2
CD133 can be used to identify colon cancer-initiating
cell populations in human tumors.18,19 Increasing evidence
suggests that cancer stem cells are more resistant to
chemotherapy and radiotherapy than other types of cancer
cells.20,21 In addition, the administration of a selective
cyclooxygenase-2 (COX-2) inhibitor can significantly in-
crease tumor susceptibility to radiation by reducing pros-
taglandin release.22 Therefore, COX-2 is a potential
predictor of tumor response to radiotherapy.
Shinto et al23 investigated whether the overexpression
of CD133 and COX-2 can be used as predictive markers of
tumor response to preoperative CRT in LARC patients. Re-
sults of both univariate and multivariate analyses indicated
that CD133 and COX-2 are independent predictors of tumor
regression grade (TRG) after preoperative CRT. Patients
lacking both CD133 and COX-2 expression have an
extremely high histopathological response rate to CRT. The
combination of CD133 and COX-2 expression is highly asso-
ciated with pathological response, which indicates the
radioresistant properties of cancer cells with putative stem
cell marker CD133 overexpression and supports the hy-
pothesis that the number of cancer stem cells in a tumor
may serve as a predictive marker of CRT resistance.
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protein expression
Several authors have demonstrated that apoptosis is one
of the mechanisms underlying chemoradiotherapy-induced
tumor regression,24 with the response to adjuvant therapy
mainly due to the ability of neoplastic cells to trigger the
apoptosis cascade. The p53 gene is involved in cell cycle
regulation, DNA repair, and cellular death through
apoptosis. p27kip1 has been identified as a member of the
universal cyclin-dependent kinase inhibitor family (Fig. 1).
More recently, it has been suggested that this protein is the
product of a putative tumor suppressor gene, that it regu-
lates cell differentiation and drug resistance in solid tu-
mors, and that it also promotes apoptosis.25 Furthermore,
Giovanni et al26 showed that the lack of p27kip1 and p53
protein expression in rectal cancer is associated with poor
response to preoperative adjuvant therapy.
(3) Potential oncogenes of cancer: b-catenin and Her-2/
neu expression
Beta-catenin is a potential oncogene in sporadic CRC.27
Her-2/neu is a therapeutic target in various malignancies.
Her-2 overexpression and amplification has also been
demonstrated in subsets of numerous types of human cancer
and is associated with poorer prognosis in many of these tu-
mors.28 In 2011, Uta et al29 analyzed expression of intra-
tumoral b-catenin (nuclear/membranous) and Her-2/neu
(cytoplasmatic/membranous) in 54 LARCpatients. They found
that low pretherapeutic membranous b-catenin protein
expression in LARC patients is associated with better histo-
logical response. Patients with higher cytoplasmatic Her-2/
neu protein expression have a significant survival benefit.29
(4) Serum molecular surrogate marker: Circulating cell-
free DNA
The circulating cell-free DNA (cfDNA) in plasma is a marker
of cancer detection.30,31 Agostini et al32 analyzed cfDNA levels
by qRT-PCR of b-globin in 67 rectal cancer patients who un-
derwent CRT. On the basis of Alu repeats, cfDNA was consid-
ered as either total (fragments of 115 bp, Alu 115) or tumoral
(fragments of 247 bp, Alu 247). Association between the pre-Figure 1 Cell cycle progression is dependent on the regu-
lated expression and activation of a set of kinases (cyclin-
dependent kinases, cdk) and cyclins. Cdk inhibitor, p27kip1,
delays cell cycle progression by inhibiting cdk activity.and post-CRT levels and also between variations during CRTof
the Alu 247, Alu 115 repeats, and Alu 247/115 ratio (cfDNA
integrity index) and pathologic tumor response was analyzed.
Results revealed that the plasma levels of longer fragments
(Alu 247) of cfDNA and the cfDNA integrity index are promising
markers of tumor response after preoperative CRT for rectal
cancer.32 This study confirmed that circulating cfDNA, and the
ratio between long and short cfDNA can be used as diagnostic
markers of rectal cancer. In addition, long cfDNA fragments
andthecfDNA integrity indexwerefound tobeassociatedwith
tumor response, and the best way to use these markers is to
evaluate their variations in plasma levels during treatment.
(5) Serum molecular surrogate marker: Circulating tumor
cells
LARC comprises primary tumors that grow beyond the
rectal wall to an extent that precludes primary surgical
removal with adequate microscopic margins. Hence, treat-
ment of LARC ismultimodal, involving preoperativeCRTaimed
at macroscopic downsizing and control of subclinical tumor
extension within the pelvic cavity, to enable complete tumor
removal by subsequent surgery. The Phase II trial Locally
Advanced Rectal CancereRadiation Response Prediction
(LARCeRRP), registered with ClinicalTrials.gov number
NCT00278694, was launched primarily to identify predictive
biomarkers of tumor radiation sensitivity, and Saelen et al33
reported that this was feasible by kinase activity profiling of
baseline tumor biopsies. The elevated kinase activity in poor-
responding tumors was suppressed by ex vivo addition of the
tyrosine kinase inhibitor sunitinib, and represented signaling
implicated in experimental radiation resistance.
(6) Resistant to chemotherapeutic drug: Thymidylate syn-
thase, thymidine phosphorylase, and dihydropyrimidine
dehydrogenase
Antimetabolite 5-fluorouracil (5-FU), which enhances
the effectiveness of radiation therapy in rectal cancer
treatment, is the standard first-line chemotherapeutic
agent for CRC.34 Thymidylate synthase (TS), thymidine
phosphorylase, and dihydropyrimidine dehydrogenase, all
involved in 5-FU metabolism, are potential biomarkers of
tumor response to 5-FU-based therapy. Low TS-expression
after neoadjuvant CRT is significantly associated with a
high TRG.35 Furthermore, Jakob et al36 demonstrated that
posttherapeutical lymph node status is the most important
prognostic marker in rectal cancer patients. Although it has
no significant influence on disease-free survival by itself,
TRG of the primary tumor after neoadjuvant CRT may well
be used as a marker for early treatment efficiency. The
measurement of posttherapeutical TS-gene expression may
help identify patients at higher risk of cancer recurrence.
Systematic laboratory data
Hyperfibrinogenemia
Elevation of plasma D-dimer levels is indicative of tumor
progression and poor prognosis in esophageal cancer, lung
cancer, and CRC.37e39 Furthermore, hyperfibrinogenemia is a
Predictors for rectal cancer following CCRT 21relevant factor associated with depth of tumor invasion and
poor prognosis in CRC.40 Kazushige41 reported that plasma
fibrinogen reduction induced by CRT is a promising biomarker
for evaluating the efficacy of CRT in rectal cancer patients.
Anemia
Hypoxia is associated with resistance to radiotherapy.42
Tumor oxygenation, expressed as hemoglobin (Hb) level,
is affected by several factors, such as adequacy of blood
supply, microcirculation, and oxygen-carrying capacity of
the blood.43 In clinical settings, normalizing the Hb level
improves tumor oxygenation.44 Serum Hb level can be a
prognostic factor influencing pathologic tumor response,
although pretreatment is not an independent prognostic
factor and pretreatment anemia (below 90 g/L of Hb) is
associated with poor response to preoperative CRT.43 In
enhancing response to preoperative CRT, anemia should be
considered for rectal cancer patients with low Hb levels.
In conclusion, tumor response is reported as tumor
down-staging associated with increased patient survival.
Histologic tumor response to preoperative treatment can
be evaluated as grade of regression. In LARC treated with
preoperative CRT, grade of regression is a significant
prognostic factor. For selected LARC patients exhibiting
good response to preoperative CRT, some effective pre-
dictive factors must be recognized. Combining conventional
prognostic markers and molecular markers as predictive
factors may warrant clarifying the guidelines for disease
management in relation to recommendations for further
concurrent CRT. In the future, well-designed and larger
clinical trials should be conducted to reflect the signifi-
cance of predictive factors. In addition, clinical data from
multiple institutions must be analyzed to develop more
sensitive, simpler, and specific biomarkers.Acknowledgments
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